Diaphragm Pacing Therapy System Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (External Diaphragm Pacemaker, Diaphragm Pacemaker), By Application (Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Others), By Region & Competition, 2020-2030F

Market Overview

Global Diaphragm Pacing Therapy System Market was valued at USD 7.71 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.06% through 2030. The Global Diaphragm Pacing Therapy System Market has witnessed steady growth in recent years, driven by factors such as the rising prevalence of respiratory disorders, technological advancements in medical devices, and increasing awareness about diaphragm pacing as an alternative therapy for certain patient populations. For instance, in Europe, respiratory disorders rank as the third leading cause of death in European Environment Agency member countries. Annually, nearly 420,000 deaths are attributed to respiratory diseases, with over 60% linked to Chronic Respiratory Diseases (CRDs) (Eurostat, 2024a; WHO, 2024; IHME, 2024). While certain countries experience higher mortality and disease burden from respiratory conditions, no consistent regional pattern has been identified.

Key Market Drivers

Rising Prevalence of Respiratory Disorders

The global healthcare landscape is witnessing a significant shift, with a concerning increase in the prevalence of respiratory disorders. These conditions can significantly impair an individual's ability to breathe, leading to a reduced quality of life and, in severe cases, life-threatening situations. However, amidst these challenges, there is a glimmer of hope for patients in the form of diaphragm pacing therapy systems. As the prevalence of respiratory disorders continues to rise, the diaphragm pacing therapy system market is poised for substantial growth. According to WHO, chronic obstructive pulmonary disease (COPD) claims over 3 million lives annually, silently impacting more than 380 million people worldwide. As the fourth leading cause of death globally, COPD has remained underrepresented in global health discussions, despite its profound effects on patients and families. It’s time to bring this noncommunicable disease to the forefront and address its devastating impact.

Respiratory disorders encompass a wide range of conditions that affect the lungs and airways, and they are increasingly becoming a global health concern. The World Health Organization (WHO) estimates that respiratory diseases account for nearly 10% of all deaths worldwide. Common conditions such as chronic obstructive pulmonary disease (COPD), asthma, and pulmonary fibrosis are on the rise, while more complex disorders like spinal cord injuries, amyotrophic lateral sclerosis (ALS), and congenital central hypoventilation syndrome (CCHS) continue to challenge patients and healthcare providers. For instance, according to the 2019 report from the National Spinal Cord Injury Statistical Center, approximately 17,730 new spinal cord injury (SCI) cases occur annually, with an estimated 249,000 to 363,000 individuals currently living with SCI in the U.S.

Diaphragm pacing therapy systems offer a ray of hope to individuals afflicted by these respiratory disorders. By stimulating the diaphragm muscles, these devices provide a way for patients to breathe more independently. They serve as an alternative to traditional mechanical ventilation methods, which can be uncomfortable, restrict mobility, and limit the patient's ability to lead a normal life. In this context, diaphragm pacing therapy systems provide a lifeline, enhancing the quality of life for patients and giving them back a sense of control and independence.

As the prevalence of respiratory disorders continues to rise, the number of patients eligible for diaphragm pacing therapy is also increasing. Conditions like ALS, spinal cord injuries, and CCHS are becoming more common, which naturally expands the potential market for these devices. Awareness about diaphragm pacing therapy systems is growing, not only among patients but also among healthcare professionals. As more physicians and caregivers recognize the benefits of this therapy, they are more likely to recommend it to eligible patients. One of the most significant drivers of market growth is the profound improvement in the quality of life that diaphragm pacing therapy offers. Patients regain independence and can once again engage in daily activities, participate in social events, and even return to work, which is a powerful motivator for patients to consider this treatment. Ongoing advancements in diaphragm pacing therapy system technology, including longer battery life, more comfortable devices, and remote monitoring capabilities, are making these systems increasingly attractive to patients and healthcare providers.

Awareness and Acceptance

In the realm of modern medicine, awareness and acceptance play pivotal roles in driving the adoption of innovative therapies and technologies. This holds particularly true for the Global Diaphragm Pacing Therapy System Market. These advanced medical devices have been a beacon of hope for individuals grappling with respiratory conditions that affect their ability to breathe independently. The growth of this market is intrinsically linked to increasing awareness about diaphragm pacing therapy systems and their acceptance among patients and healthcare professionals. For instance, Synapse Biomedical obtained Emergency Use Authorization (EUA) from the U.S. FDA for its TransAeris diaphragm pacing therapy system. Previously, the TransAeris system received CE Mark approval in 2018 and is currently undergoing clinical trials in the U.S.

When individuals and their families are aware of the existence and effectiveness of diaphragm pacing therapy systems, they can actively seek out these solutions. Awareness empowers patients to be advocates for their own health, and this leads to an increased demand for the therapy. Healthcare professionals play a crucial role in the decision-making process. As awareness about diaphragm pacing therapy systems grows, physicians become more knowledgeable about the treatment options available. This, in turn, leads to more frequent recommendations of diaphragm pacing therapy to eligible patients. Patients with respiratory conditions often find solace and guidance in support communities. When these communities promote awareness and share success stories related to diaphragm pacing therapy, it encourages more individuals to explore this treatment option.

For patients and healthcare providers, the most critical aspect is the efficacy and safety of diaphragm pacing therapy. As clinical evidence accumulates and demonstrates the benefits and safety of these systems, acceptance naturally follows. Real-life success stories from patients who have experienced improved quality of life through diaphragm pacing therapy are powerful drivers of acceptance. These testimonials humanize the therapy, making it more relatable and less daunting. To encourage acceptance, the medical community needs to be educated about the therapy. Continuing medical education programs, seminars, and research dissemination help bridge the knowledge gap and foster acceptance. Acceptance is closely tied to financial considerations. Wider acceptance is facilitated by the availability of reimbursement options and insurance coverage, which reduce the financial burden on patients.

Quality of Life Improvement

The Global Diaphragm Pacing Therapy System Market is currently experiencing remarkable growth, driven by a range of factors, one of the most significant being the tangible and profound improvement in the quality of life that diaphragm pacing therapy provides to patients. As the market continues to expand, the elevation of life quality for those affected by respiratory disorders becomes a pivotal force driving the adoption of these innovative medical devices.

Respiratory disorders can be debilitating, making everyday activities a challenge and limiting one's independence. For individuals living with conditions such as spinal cord injuries, amyotrophic lateral sclerosis (ALS), or congenital central hypoventilation syndrome (CCHS), a significant part of their lives may be defined by their reliance on mechanical ventilation, which can hinder mobility and restrict their ability to engage fully in life.

One of the most significant benefits of diaphragm pacing therapy is that it enables patients to regain their independence. They can breathe more naturally, reducing the need for constant monitoring and assistance. These systems allow patients to lead more mobile lives. They can move freely, participate in daily activities, and engage in social events, which were often severely limited while using traditional mechanical ventilation. The improved quality of life associated with diaphragm pacing therapy encourages social integration. Patients can go back to work, attend family gatherings, and participate in community events, leading to a sense of belonging and well-being. The emotional and psychological well-being of patients significantly improves when they are not constantly tethered to machines. They experience reduced stress and anxiety, leading to a better overall quality of life.

The potential for a heightened quality of life is a potent motivator for patients to consider diaphragm pacing therapy. They are more willing to explore this treatment option because of the promise of a better life. Quality of life improvements are often considered just as important as the medical benefits of the therapy, making it an attractive choice.

Expanding Applications

The Global Diaphragm Pacing Therapy System Market is poised for significant expansion, and one of the key factors driving its growth is the exploration of expanding applications beyond its traditional uses. As medical science continues to evolve, researchers and healthcare professionals are uncovering new possibilities for diaphragm pacing therapy systems, offering fresh hope to patients with a wider range of medical conditions.

The initial application of diaphragm pacing therapy systems was primarily focused on addressing respiratory challenges in individuals with spinal cord injuries, amyotrophic lateral sclerosis (ALS), and congenital central hypoventilation syndrome (CCHS). These systems provided a lifeline for those who faced compromised respiratory function.

COPD is a global health concern, and patients often struggle with breathing difficulties. Diaphragm pacing therapy is now being explored as a potential option for individuals with COPD who do not respond to traditional treatments. The expanding application of this therapy to COPD patients presents an exciting opportunity to address a broader patient population. The list of neuromuscular disorders that could benefit from diaphragm pacing therapy continues to grow. This includes conditions such as Duchenne muscular dystrophy, myotonic dystrophy, and Guillain-Barré syndrome. As the medical community explores the applicability of diaphragm pacing in these conditions, it opens new avenues for growth. Beyond neuromuscular disorders, there are numerous conditions characterized by respiratory muscle weakness. These encompass a range of diseases and injuries that impact the muscles required for breathing. Diaphragm pacing therapy systems offer potential solutions to patients with these diverse conditions.

The expansion of applications broadens the pool of eligible patients who can benefit from diaphragm pacing therapy. As more conditions become treatable with this technology, the potential market for these systems grows significantly. Healthcare professionals play a crucial role in driving the adoption of diaphragm pacing therapy. As they become more aware of the expanding applications, they are more likely to recommend it to eligible patients, further facilitating market growth. Patients, too, are more likely to consider diaphragm pacing therapy when they have options for treating their specific condition. The availability of this therapy for a wider range of diseases gives patients greater choice and control over their treatment. Ongoing research and development efforts by medical device manufacturers are at the forefront of expanding applications. These efforts lead to the development of new and improved diaphragm pacing systems designed to address a broader spectrum of conditions. 

Download Free Sample Report

Key Market Challenges

High Initial Costs

One of the most prominent challenges in the diaphragm pacing therapy system market is the high initial costs associated with these devices. The sophisticated technology and intricate surgical procedures required for implantation can result in substantial expenses for both healthcare facilities and patients. The cost may act as a deterrent, limiting access to those who may benefit from diaphragm pacing therapy.

Reimbursement Issues

The lack of comprehensive insurance coverage and reimbursement for diaphragm pacing therapy presents a significant hurdle. In many regions, patients may struggle to secure financial support for these treatments. Limited insurance coverage may force individuals to opt for alternative treatments or endure the financial burden themselves, hindering the market's growth.

Technical Challenges

Diaphragm pacing therapy systems require precise surgical implantation and ongoing technical support. Maintaining these systems and addressing technical issues can be complex, which may deter healthcare facilities from offering these treatments and patients from considering them.

Key Market Trends

Enhanced Device Technology

One of the most prominent trends in the diaphragm pacing therapy system market is the ongoing enhancement of device technology. Manufacturers are investing in research and development to create more advanced, efficient, and patient-friendly systems. This includes devices with improved battery life, wireless connectivity for remote monitoring, and more compact designs for enhanced comfort.

Regulatory Advances

As the medical community continues to recognize the potential of diaphragm pacing therapy, regulatory advances are expected. Improved and streamlined approval processes for diaphragm pacing devices will encourage innovation and accelerate market growth. Regulatory bodies are likely to work more closely with manufacturers to ensure safety and effectiveness.

Patient Advocacy and Awareness

Patient advocacy groups are increasingly promoting awareness about diaphragm pacing therapy and offering support for patients. This trend is instrumental in educating both patients and healthcare professionals about the benefits and availability of diaphragm pacing therapy.

Segmental Insights

Product Insights

Based on the category of Product, the external diaphragm pacemaker category held a leading position in the market in 2024, representing the highest share of revenue. This segment has been experiencing increased recognition due to the growing demand for treating conditions like cervical spinal cord injury and congenital central hypoventilation syndrome. The diaphragm pacemaker addresses concerns related to power interruptions and the need for an external power source. Its mobility and noiseless operation contribute to the expansion of the market.

Download Free Sample Report

Regional Insights

In 2024, North America asserted its dominance in the diaphragm pacing therapy system market, securing the largest share of revenue. Anticipated market growth in this region during the forecast period can be attributed to the high incidence of respiratory disorders, such as sleep apnea, amyotrophic lateral sclerosis, and spinal cord injuries. The region is poised to benefit from increased healthcare spending and rising disposable incomes among patients, which are expected to contribute to market expansion.

In the Asia Pacific region, the market is forecasted to experience the most rapid growth. This is primarily due to the increasing prevalence of respiratory disorders, augmented healthcare expenditure, supportive governmental initiatives, a growing emphasis on research and development efforts, and technological advancements aimed at enhancing healthcare infrastructure.

Recent Developments

• In July 2023, a study explored diaphragm pacing (DP) in Pompe disease, an inherited condition caused by acid-α-glucosidase (GAA) deficiency, often leading to respiratory failure. Six ventilator-dependent patients (three pediatric) underwent DP implantation and conditioning, involving daily low-intensity stimulation. Results showed improved ventilator-free tolerance and stabilized breathing over time, with three patients achieving increased or stable minute ventilation. DP demonstrated feasibility, minimal adverse events, and long-term respiratory stability, offering potential benefits for Pompe patients.

• In March 2023, the FDA approved the NeuRx Diaphragm Pacing System (P200018) to aid breathing in patients with high spinal cord injuries. It uses electrical impulses to stimulate diaphragm muscles, reducing reliance on mechanical ventilators. The system includes implanted electrodes, an external pulse generator, and a patient controller. Studies showed it enabled 90% of users to breathe independently for at least four hours daily and 60.8% for 24 hours.
• In July 2021, diaphragm pacing (DP) was highlighted as a promising approach to respiratory rehabilitation after cervical spinal cord injury (CSCI). While mechanical ventilation is vital for patients, it can cause diaphragm atrophy. DP offers an alternative, promoting ventilator weaning, neuromuscular plasticity, and improved respiratory function. Early DP use may enhance diaphragm health and recovery through task-specific training. As adoption grows, there is an opportunity to refine rehabilitation models, optimize DP benefits, and advance respiratory care for CSCI patients.
• Lungpacer Medical received emergency use authorization approval from the U.S. FDA on April 14, 2020, allowing the deployment of diaphragm pacing therapy systems to assist COVID-19 patients. On May 11, 2016, the Lungpacer Diaphragm Pacing System was granted approval through the Expedited Access Pathway (EAP) Designation by the U.S. FDA.

Key Market Players

• LUNGPACER MEDICAL INC.
• Avery Biomedical Devices, Inc.
• Synapse Biomedical Inc
• Astrotech Corp.
• AstraZeneca PLC
• Novartis AG
• Boehringer Ingelheim
• Respironics Ltd
• Johnson & Johnson (Actelion)
• PneumRx, LLC

Report Scope:

In this report, the Global Diaphragm Pacing Therapy System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Diaphragm Pacing Therapy System Market, By Product:

o   External Diaphragm Pacemaker

o   Diaphragm Pacemaker

• Diaphragm Pacing Therapy System Market, By Application:

o   Spinal Cord Injury

o   Amyotrophic Lateral Sclerosis

o   Others

• Diaphragm Pacing Therapy System Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  Germany

§  United Kingdom

§  France

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  Japan

§  India

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diaphragm Pacing Therapy System Market.

Available Customizations:

Global Diaphragm Pacing Therapy System market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Diaphragm Pacing Therapy System Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com